Skip to main content
SpringerLink
Log in

Somatische Tumormutationen eröffnen neue Therapieoptionen

Translationale Onkologie

  • Wissenschaft
  • Published:
BIOspektrum Aims and scope

Abstract

Prognostic or predictive somatic genetic biomarkers influence therapeutic decisions in oncology. With the availability of next-generation sequencing (NGS) technologies, large numbers of somatic and germ line mutations can be analysed in parallel both, from formalin-fixed, paraffin-embedded tissue (FFPE) and fresh frozen tissue at high quality. In this study we evaluated the feasibility, turn-around time and diagnostic usefulness of highthroughput NGS analyses in the clinical setting and offered two different diagnostic sequencing panels to 52 selected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Amado RG, Wolf M, Peeters M et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634

    Article  PubMed  CAS  Google Scholar 

  2. Lièvre A, Bachet J-B, Boige V et al. (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379

    Article  PubMed  CAS  Google Scholar 

  3. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507–2516

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  4. Metzker ML (2010) Sequencing technologies — the next generation. Nat Rev Genet 11:31–46

    Article  PubMed  CAS  Google Scholar 

  5. Vogelstein B, Papadopoulos N, Velculescu VE et al. (2013) Cancer genome landscapes. Science 339:1546–1558

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Prahallad A, Sun C, Huang S et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483:100–103

    Article  PubMed  CAS  Google Scholar 

  7. Gonzalez-Perez A, Mustonen V, Reva B et al. (2013) Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods 10:723–729

    Article  PubMed  CAS  Google Scholar 

  8. Roychowdhury S, Iyer MK, Robinson DR et al. (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3:111ra121

    Article  PubMed Central  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Medizinische Genetik und Angewandte Genomik, Universitätsklinikum Tübingen, Tübingen, Germany

    Christopher Schroeder, Peter Bauer & Olaf Riess

  2. Genes and Therapy GmbH, Tübingen, Germany

    Christopher Schroeder, Peter Bauer & Olaf Riess

  3. Institut für Pathologie und Neuropathologie, Universitätsklinikum Tübingen, Tübingen, Germany

    Falko Fend

  4. Institut für Medizinische Genetik und Angewandte Genomik, Universitätsklinikum Tübingen, Calwerstraße 7, D-72076, Tübingen, Germany

    Christopher Schroeder

Authors
  1. Christopher Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Falko Fend
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Olaf Riess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Schroeder.

Additional information

Christopher Schroeder Jahrgang 1982. Medizinstudium an der Universität Tübingen. Studium der Medizinischen Informatik an der Beuth Univer sity of Applied Sciences, Berlin. 2009–2011 Radioonkologie, Universitätsklinikum Tübingen. Seit 2012 Institut für Medizinische Genetik und Angewandte Genomik, Universitätsklinikum Tübingen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schroeder, C., Bauer, P., Fend, F. et al. Somatische Tumormutationen eröffnen neue Therapieoptionen. Biospektrum 20, 136–140 (2014). https://doi.org/10.1007/s12268-014-0417-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12268-014-0417-2

Search

Navigation